SLC5A2 and heart failure: The sodium glucose cotransporter type 2 (SGLT-2) inhibitor empagliflozin has been demonstrated to reduce cardiovascular mortality by 38% and heart failure (HF) hospitalizations by 35% in patients with type 2 diabetes (T2DM) in the EMPA-REG OUTCOMES clinical trial [1, 2].